(c) Guardian News & Media Ltd
About Prevtec Microbia
Estimated value of the global animal health industry by 2020*
Number of countries where Coliprotec® F4 is approved for use
We have been devising innovative solutions to challenges in livestock production for over a decade.
Prevtec Microbia is proud to announce that it recently submitted a dossier to the European regulatory authorities, for the approval of its Coliprotec® F4/F18. This live bacterial vaccine for oral administration will offer a broader spectrum than the Coliprotec F4 vaccine presently available in the European Union. It will allow for the immunization of pigs against both E. coli enterotoxinogenic F4 and E. coli enterotoxinogenic F18 bacteria associated with post-weaning diarrhea in swine. Coliprotec F4/F18 will therefore contribute to the reduction of antibiotic use in European swine operations.
Prevtec Microbia’s scientific and regulatory team has successfully managed this filing and takes this opportunity to underscore the support of its partners, Elanco and Klifovet in making this project successful.
Antimicrobial resistance (AMR) is resistance of a microorganism to an antimicrobial medicine to which it was originally sensitive. AMR occurs naturally but the phenomenon is hugely increased by excessive and inappropriate use of antimicrobial medicines and poor infection control practices in animals and humans.
Source: European Commission, http://europa.eu/rapid/press-release_STATEMENT-15-6097_en.htm
25 000 patients die annually in the EU alone as a result of infections caused by resistant bacteria. Globally this number could be as high as 700 000.
Source: European Commission, http://ec.europa.eu/dgs/health_food-safety/docs/amr_factsheet.pdf